 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
1 News |  |
- | lecinoxoid (VB-703) / VBL Therapeutics
Preclinical, Journal, IO Biomarker: Treatment with Lecinoxoids Attenuates Focal and Segmental Glomerulosclerosis Development in Nephrectomized Rats. (Pubmed Central) - May 30, 2019
Moreover, inhibiting monocyte migration can also contribute to treatment of FSGS. Our data demonstrate that targeting TLR2-4 and/or monocyte migration, directly affects the priming phase of fibrosis and may consequently perturb disease parthogenesis.